.
MergerLinks Header Logo

New Deal


Announced

Mérieux Equity Partners to acquire a majority stake in InnoSyn.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pending

research and development

Chemicals: Diversified

Cross Border

Friendly

Single Bidder

Majority

Private

Private Equity

Netherlands

Acquisition

Synopsis

Edit

Mérieux Equity Partners, an European healthcare-specialized investment firm, agreed to acquire a majority stake in InnoSyn, a provider of outsourced process R&D services. Financial terms were not disclosed. “When we first met InnoSyn’s Management team, we were immediately impressed by their expertise and the unique positioning of the Company in its sector. We believe that InnoSyn, already being one of the European leaders, is still only at its beginning, providing enormous potential for further development through the continuation of its R&D services, where it has built true excellence, coupled with strategic expansion of its geographical coverage, and broadening its range of services to adjacent activities. We are excited to start collaborating with the Management team to accompany InnoSyn in its next development phase," Jaana Grüter and Theodor Wuppermannn, MxEP Partner and Managing Director.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US